Small Molecule HTT Modulators for Non-Invasive Huntington's Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease are invasive, have uncertain distribution within the brain, and do not address peripheral dysfunction, highlighting the need for small molecule modulators of the huntingtin protein that can be delivered systemically and non-invasively to treat the symptoms and delay disease progression.
Innovation Solution
Development of compounds that modulate the huntingtin protein, including isotopically enriched analogs, pharmaceutically acceptable salts, prodrugs, tautomers, and stereoisomers, which can be administered as pharmaceutical compositions to treat Huntington's disease by targeting the protein implicated in neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotide or AAV-miR mediated HTT RNA degradation is used, then mHTT levels are reduced in the CSF, but the treatment becomes invasive requiring repeated intrathecal injections
Solution Approach 1:
The patent transitions from nucleic acid-based therapies (ASO, AAV-miR) to small molecule compounds that modulate HTT protein function. This parameter change in molecular class enables oral/systemic administration routes, eliminating the need for invasive intrathecal injections while maintaining therapeutic efficacy in reducing mHTT levels and addressing peripheral dysfunction.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that can cross the blood-brain barrier and modulate HTT protein function. These small molecules serve as a bridge between systemic administration and central nervous system target sites, enabling non-invasive delivery while achieving the desired therapeutic effect of mHTT lowering and addressing both brain and peripheral dysfunction.
2Reliability
If antisense oligonucleotide or AAV-miR mediated HTT RNA degradation is used, then mHTT levels are reduced, but distribution throughout the brain to all affected regions is not certain
Solution Approach 1:
The small molecule compounds described in the patent possess the ability to distribute throughout the brain and modulate HTT protein function in multiple affected regions simultaneously. These compounds can address both central and peripheral dysfunction, providing universal coverage across all brain regions and peripheral tissues where mHTT exerts pathological effects, unlike the localized distribution of ASO or AAV-miR therapies.
3Ease of operation
If current palliative treatments are used, then symptom severity is lessened, but disease progression is not delayed and no disease modifying effect is achieved
Solution Approach 1:
The patent extracts the disease-modifying capability from palliative symptom management by developing small molecule compounds that directly target and modulate the underlying pathological mechanism - the huntingtin protein. Rather than merely managing symptoms, these compounds address the root cause by reducing mHTT levels and function, thereby delaying disease progression and providing true disease modification while still managing symptoms.
Data Source
AI summary
Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.